glp 1 isn't working Maximum Dose of your GLP-1 Working? Here's Why 7 Reasons You Aren't Losing

However, major expansion of the GLP-1 receptor agonist market in the US is fueled by heavy investments in research and development of new therapies by many pharmaceutical industries

doi: 10.1007/978-3-211-79280-3_949 81 NCT06864026

A once-weekly formulation of exenatide has been developed by Amylin Pharmaceuticals and has been marketed by AstraZeneca since 2012 under the trade name Bydureon

As well see later when we go into the data, this still is not a magic shot - its worth noting that it still takes nearly a year for these outcomes to happen (and likely many patients will be n maintenance doses as they continue to lose weight beyond those timeframes)

Back D'Alessio, DA, Marks, V (Dec 2023) 'Glucagon as the first incretin: objects (in the rearview mirror) are closer than they appear', Diabetes , 72, 173940